On November 28, Foresee Pharmaceuticals announced that its innovative formulation drug, CAMCEVI 42mg, developed for treating advanced prostate cancer in adults, has been granted market authorization in the United Kingdom. The company’s licensing partner will oversee commercialization efforts to capture opportunities in the UK, the world's fifth-largest pharmaceutical market.

Foresee explained that its licensing partner, Accord Healthcare, submitted a New Drug Application (NDA) for CAMCEVI 42mg Prolonged-Release Suspension for Injection to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on July 26, 2022. On November 27, 2024, Foresee received confirmation from Accord Healthcare that the MHRA had completed its review and granted market authorization for the drug.

Foresee highlighted the growing demand for prostate cancer treatments in aging societies. According to Nova One Advisor, the global prostate cancer drug market was valued at approximately USD 16.46 billion in 2022 and is projected to grow to USD 36.54 billion by 2032, with a compound annual growth rate (CAGR) of approximately 8.3%.

Additionally, data from Precision Reports indicate that the global leuprolide market (across all indications) was valued at approximately USD 2.455 billion in 2021 and is expected to reach USD 3.264 billion by 2027, reflecting a CAGR of 4.86%.

Foresee emphasized that CAMCEVI 42mg is developed using its proprietary sustained-release injection platform. This prefilled, six-month sustained-release formulation addresses long-standing challenges associated with conventional high-activity leuprolide injections, which require manual mixing. The new formulation significantly improves user convenience and reduces potential errors associated with manual preparation, marking a breakthrough in prostate cancer treatment.

Resource: 逸達前列腺癌新劑型新藥 CAMCEVI 42毫克 獲英國上市許可